References
- Huertas A, Girerd B, Dorfmuller P, O’Callaghan D, Humbert M, Montani D. Pulmonary veno-occlusive disease: advances in clinical management and treatments. Expert Rev. Resp. Med.5(2), 217–231 (2011).
- Mathai SC, Hassoun PM. Pulmonary arterial hypertension associated with systemic sclerosis. Expert Rev. Resp. Med.5(2), 267–279 (2011).
- Sluiter I, Reiss I, Kraemer U, de Krijger R, Tibboel D, Rottier RJ. Vascular abnormalities in human newborns with pulmonary hypertension. Expert Rev. Resp. Med.5(2), 245–256 (2011).
- Zuckerman WA, Rosenzweig EB. Pulmonary hypertension in children with sickle cell disease. Expert Rev. Resp. Med.5(2), 233–243 (2011).
- Cicalini S, Chinello P, Petrosillo N. HIV infection and pulmonary arterial hypertension. Expert Rev. Resp. Med.5(2), 257–266 (2011).
- Cool CD, Voelkel NF, Bull T. Viral infection and pulmonary hypertension: is there an association? Expert Rev. Resp. Med.5(2), 207–216 (2011).
- Arena R, Guazzi M, Myers J, Grinnen D, Forman DE, Lavie CJ. Cardiopulmonary exercise testing in the assessment of pulmonary hypertension. Expert Rev. Resp. Med.5(2), 281–293 (2011).
- Frantz RP. Hemodynamic monitoring in pulmonary arterial hypertension. Expert Rev. Resp. Med.5(2), 173–178 (2011).
- Mukherjee B, Howard L. Combination therapy in pulmonary arterial hypertension: do we have the right strategy? Expert Rev. Resp. Med.5(2), 191–205 (2011).
- Hagan G, Pepke-Zaba J. Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds. Expert Rev. Resp. Med.5(2), 163–171 (2011).
- Lasker GF, Maley JH, Pankey EA, Kadowitz PJ. Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. Expert Rev. Resp. Med.5(2), 153–161 (2011).
- Ewert R, Gläser S, Bollmann T, Schäper C. Inhaled iloprost for therapy in pulmonary arterial hypertension. Expert Rev. Resp. Med.5(2), 145–152 (2011).
- Shlobin OA, Nathan SD. Pulmonary hypertension secondary to interstitial lung disease. Expert Rev. Resp. Med.5(2), 179–190 (2011).